Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

BAKKAFROST: Share Savings Plan Transaction

As a part of the share savings plan for employees in 2020, the following primary insiders have purchased Bakkafrost shares: · Regin Jacobsen, CEO, purchased 26 shares. After the transaction, he holds 4,616,680 shares. · Odd Eliasen, Managing Director, purchased 21 shares. After the transaction, he holds 184,419 shares. · Høgni Dahl Jakobsen, CFO, purchased 16 shares. After the transaction, he holds 346 shares. · Annika Frederiksberg, Board Member, purchased 8 shares. After the transaction, she holds directly and indirectly 16,042 shares. The shares were purchased from P/F

Cyxone revises the development plan for Rabeximod

Cyxone AB (publ), a Swedish biotech company dedicated to developing improved treatments for autoimmune diseases, announces today that it has initiated a process to optimize the development plan for Rabeximod. This initiative is based on valuable input from the company’s new senior medical advisors, updated market intelligence and the opportunity to prolong market exclusivity through newly filed patent applications. In parallel, the company is preparing a phase 2 clinical study of Rabeximod in Covid-19 patients, with a potential initiation already in the fourth quarter of 2020.With a new CEO

Primary insider disclosure

The following primary insiders (or their related parties as described below) have, as part of the company's incentive program, committed to acquire shares in Ocean Yield ASA (the "Company" or "Ocean Yield"): · Lars Solbakken, CEO of Ocean Yield ASA, has through his wholly owned company Finmarine AS acquired 30,000 shares in Ocean Yield. Upon completion of such acquisition, Lars Solbakken will own, directly or indirectly, 1,670,880 shares in the Company. · Eirik Eide, CFO of Ocean Yield ASA, has through his wholly owned company Kleiver Invest AS acquired 30,000 shares in Ocean Yield.

Africa Energy to Present at Virtual Town Hall Meeting

VANCOUVER, BC, September 24, 2020 /CNW/ – Africa Energy Corp. (TSX Venture: AFE, Nasdaq First North Growth Market: AEC) (“Africa Energy” or the “Company”), an oil and gas company with exploration assets offshore South Africa and Namibia, will host a virtual town hall meeting on Wednesday, September 30, 2020, at 18:00 CEST (12:00 EDT). Mr. Garrett Soden, President and CEO, and Mr. Jan Maier, VP Exploration, will present an update on the company’s operations including the current exploration drilling program underway on Block 11B/12B offshore South Africa. All are welcome to join.

The first Brazilian Gripen has flown in Brazil

Today, September 24, the first Brazilian Gripen E, designated by Brazilian Air Force (FAB) as F-39 Gripen, concluded its first flight in Brazil. The aircraft flew from the airport in Navegantes to Embraer´s facility in Gavião Peixoto.The official presentation of the aircraft is scheduled to take place during the Aviator’s Day and the Brazilian Air Force Day ceremony in Brasilia, celebrated on the 23[rd] of October. “Gripen's arrival in Brazil and its first flight are major milestones in the Brazilian Gripen programme. We are proud of this journey alongside so many qualified and committed

Hansa Biopharm announces positive high-level data from investigator-initiated phase 2 trial with imlifidase to treat anti-GBM disease

Study concludes that imlifidase leads to rapid clearance of anti-GBM antibodies, with two-thirds of patients achieving dialysis independence six months after treatment Positive data demonstrates potential to increase renal survival in anti-GBM antibody disease and marks an important milestone for expansion of imlifidase outside transplantationLund, Sweden September 24, 2020. Hansa Biopharma (“Hansa”), the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announces positive high-level data from an investigator-initiated phase 2 trial that evaluated safety,

Magnolia Bostad AB (publ) announces final tender results for certain senior unsecured bonds

NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED) OR IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS DOCUMENT. THE DISTRIBUTION OF THIS DOCUMENT IN CERTAIN JURISDICTIONS (IN PARTICULAR, THE UNITED STATES AND

Look forward to the afterlife with Stellaris: Necroids Species Pack, Coming Soon

Stellaris and all expansions heavily discounted on Steam NowSTOCKHOLM - Sept 24, 2020 - Paradox Interactive, a publisher and developer of games that thrive on the dark side of the moon, has today announced Necroids - the next species pack for its grand strategy sci-fi game, Stellaris.   With the Necroids Species Pack, Stellaris gamers will learn that death is not the end, but rather the beginning of their intergalactic journey as new changes reincarnate playthroughs of Stellaris for long time players, as well as bringing new undeath to established playtypes. To live amongst the Necroids,

Design of Tellus Towers impacted by changes in plans for developing Telefonplan

The design of SSM’s Tellus Towers joint venture project at Stockholm’s Telefonplan will change as a result of a Stockholm City Planning Board decision regarding the development of central Telefonplan. As a result, 1,500 homes that were originally planned in the area will be reduced to about 1,000 and the two Tellus Towers skyscrapers will be replaced with a group of high-rise buildings. The intention is to create a greater variation of homes and a neighborhood that better blends in with Stockholm’s existing skyline. The decision is not expected to impact SSM’s results for Q3 or the full year

Swany and Polygiene takes personal safety essentials to a new level with a ViralOff® series

With more than 90 years of cutting-edge research, design, and manufacturing experience, Swany is committed to providing the best in performance products. Now, together with Polygiene, they have created an entire range of self-sterilizing, anti-microbially treated products featuring masks, gloves, balaclavas, and neck gaiters. The idea is to give people a range of products that are close to mouth, hands, nose and eyes – and to make them essentially self-cleaning when it comes to viruses. Since they not only inhibit viruses but also odors, they do not need to be washed and will

Swedencare AB (publ) intends to carry out a directed new share issue as part of the financing of the acquisitions of Nutravet (UK) Limited and the operations conducted by Animal Pharmaceuticals Inc.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Swedencare AB (publ) (”Swedencare” or the ”Company”) today announces its intention to carry out a directed new share issue of approximately SEK 300 million to Swedish and

Swedencare AB (publ) acquires the operations of an American Pet Health company focused on the Veterinary sector

Non-official translation of the original Swedish press release Swedencare AB (publ) (”Swedencare”) acquires the operations of the American Pet Health company, Animal Pharmaceuticals Inc. (”Animal Pharmaceuticals”). The purchase price amounts to approximately 131 million SEK with a possible additional purchase price of maximum 87 million SEK, dependent on the additional purchase price the cash consideration will consist of approximately 91-178 million SEK and a directed new share issue of 251 994 shares in Swedencare to the seller upon closing, which is expected to take place on October 1st,

Swedencare AB (publ) acquires leading British Animal Health company

Non-official translation of the original Swedish press release Swedencare AB (publ) (”Swedencare”) acquires 100% of the British company Nutravet (UK) Limited (“Nutravet”). The purchase price amounts to approximately 375 million SEK and consists of a cash amount of approximately 281 million SEK and a directed new share issue of 580 769 shares in Swedencare to the seller upon closing, which is expected to take place on October 1st, 2020. Through the acquisition Swedencare will receive a comprehensive and unique product portfolio of nutraceuticals in the premium segment for dogs, cats and

UNITED BANKERS CORPORATION: ACQUISITION OF OWN SHARES 24.09.2020

United Bankers Corporation NOTIFICATION 24.09.2020 at 18:30 UNITED BANKERS CORPORATION: ACQUISITION OF OWN SHARES 24.09.2020 Date 24.09.2020Exchange transaction BuyShare class UNIAVAmount 1,850Average price/share 8.7000 EURHighest price/share 8.7000 EURLowest price/share 8.7000 EURTotal price 16,095.00 EUR The shares held by United Bankers Corporation on 24.09.2020: UNIAV 16,385   On behalf of United Bankers Corporation  Skandinaviska Enskilda Banken AB (Publ) Antti

Asetek A/S Announces Transactions Carried Out Under the Current Share Buyback Programme in Accordance With the "Safe Harbour Method"

September 24, 2020 - On May 19, 2020, Asetek A/S launched a share buyback programme, as described in company announcement of May 19, 2020. According to the programme, Asetek A/S will in the period until September 30, 2020 buy back own shares up to a maximum value of USD 4.5 million and with a maximum of 1,038,082 shares. The share buyback programme will be implemented in accordance with Regulation (EU) no. 596/2014 of 16th April 2014 of the European Parliament and Council and  ommission Delegated Regulation (EU) no. 2016/1052, also referred to as the Safe Harbour rules. Trading day

Realfiction announces a clarification regarding its patent pending ECHO display technology

Realfiction Holding AB (“Realfiction”) announces a clarification on the status of the company’s patent-pending ECHO 3D display technology. This clarification is published in response to the many questions received from shareholders related to the press release on the publication of the international ECHO patent application, and presentation of more detailed information on the technology, that was published earlier today.“The whole Realfiction team is excited about the strong shareholder interest in our ECHO technology, and we always strive to deliver up-to-date information on our progress.

BioStock: Chordate Medical tackles chronic migraines

About every seventh person in Sweden suffers from migraine – a disease characterised by intense and throbbing headaches in combination with a number of other ailments. Patients suffering from chronic migraine have headaches every other day, on average, which leads to an enormous burden on both the individual and on society as a whole. Chordate Medical wants to play a part in reducing this burden with a treatment called Kinetic Oscillation Stimulation – a fast, nerve-stimulating treatment with the potential to be both long-lasting and without unexpected side effects.Read the full article at

Alligator Bioscience launches a new immuno-oncology concept

Lund, Sweden, September 24, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that the company launches a new concept for patient specific immunotherapy, called Neo-X-Prime. Alligator presents the concept at the scientific congress 11th World Bispecific Summit held September 22-24, 2020. The new concept, based on Alligator’s bispecific format RUBY™, build on bispecific antibodies that physically connect tumor debris from the patient’s cancer cells with the relevant immune cells, resulting in strong and tumor selective immune activation. This is thought to increase

ContextVision - Company presentation held at shareholder Webinar

Stockholm, September 24[th], 2020 – Today ContextVision presented the company at a shareholder webinar arranged by Norne and ContextVision. CEO Fredrik Palm gave an update of the company’s development and shared the company’s future direction. Please find a PDF-version of the presentation attached. The presentation will also be published on the company's website. For further information, please contact ContextVision’s CEO, Fredrik Palm, at +46 76 870 25 43 or visit www.contextvision.com. ### About ContextVision ContextVision is a medical technology software company

#20-339 Delisting of Derivatives from NGM

Information about certain derivatives that will be delisted from NGM.For more details, see attached files. For further information concerning this NGM notice please contact: Listing department on +46 8 566 390 20 or at listings@ngm.se Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete

#20-338 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact: Listing on +46 8 566 390 20 or at listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for

Solteq Plc issues new notes in a nominal amount of EUR 23 million and redeems its outstanding notes due 2021

Solteq Plc, Inside information, 24 September 2020 at 5:15 pm EESTSolteq Plc (“Solteq” or the “Company”) issues new euro-denominated senior unsecured fixed rates notes in a nominal amount of EUR 23 million (the “New Notes”). The New Notes, which will mature on 1 October 2024, are targeted mainly to institutional investors and are callable before their final maturity. The New Notes have an issue price of 100 per cent of their nominal amount and bear a fixed interest rate of 6.00 per cent per annum. The proceeds from the issue will be used for the refinancing of the Company’s existing notes

There are no items matching the current filter
There are no more items matching the current filter
Back to top